Emerging drugs for the treatment of symptoms associated with autism spectrum disorders

Logan K. Wink, Martin H. Plawecki, Craig A. Erickson, Kimberly A. Stigler, Christopher J. McDougle

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Importance of the field: Autism spectrum disorders, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders defined by qualitative impairment in social interaction, impaired communication and stereotyped patterns of behavior. The most common forms of PDD are autistic disorder (autism), Asperger's disorder and PDD not otherwise specified. Recent surveillance studies reveal an increase in the prevalence of autism and related PDDs. The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families. Areas covered in this review: This review examines results from neurobiologic research in an attempt to both elucidate the pathophysiology of autism and guide the development of pharmacologic agents for the treatment of associated symptoms. The safety and efficacy data of drugs currently in clinical use for the treatment of these symptoms, as well as pharmaceuticals currently under development, are discussed. What the reader will gain: This comprehensive review will deepen the reader's current understanding of the research guiding the pharmacologic treatment of symptoms associated with autism and related PDDs. Areas of focus for future research are also discussed. The need for large-scale investigation of some commonly used pharmacologic agents, in addition to the development of drugs with improved efficacy and safety profiles, is made evident. Take home message: Despite progress in the development of pharmacologic treatments for a number of interfering symptom domains associated with autism and other PDDs, a great deal of work remains.

Original languageEnglish
Pages (from-to)481-494
Number of pages14
JournalExpert Opinion on Emerging Drugs
Volume15
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Autistic Disorder
Pharmaceutical Preparations
Asperger Syndrome
Stereotyped Behavior
Safety
Interpersonal Relations
Research
Autism Spectrum Disorder
Communication

Keywords

  • Aripiprazole
  • Autism
  • Autistic disorder
  • Methylphenidate
  • PDDs
  • Risperidone
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Wink, L. K., Plawecki, M. H., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2010). Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opinion on Emerging Drugs, 15(3), 481-494. https://doi.org/10.1517/14728214.2010.487860

Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. / Wink, Logan K.; Plawecki, Martin H.; Erickson, Craig A.; Stigler, Kimberly A.; McDougle, Christopher J.

In: Expert Opinion on Emerging Drugs, Vol. 15, No. 3, 09.2010, p. 481-494.

Research output: Contribution to journalArticle

Wink, Logan K. ; Plawecki, Martin H. ; Erickson, Craig A. ; Stigler, Kimberly A. ; McDougle, Christopher J. / Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. In: Expert Opinion on Emerging Drugs. 2010 ; Vol. 15, No. 3. pp. 481-494.
@article{4c00dc73bf9e4cf28d8a88903827b8a5,
title = "Emerging drugs for the treatment of symptoms associated with autism spectrum disorders",
abstract = "Importance of the field: Autism spectrum disorders, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders defined by qualitative impairment in social interaction, impaired communication and stereotyped patterns of behavior. The most common forms of PDD are autistic disorder (autism), Asperger's disorder and PDD not otherwise specified. Recent surveillance studies reveal an increase in the prevalence of autism and related PDDs. The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families. Areas covered in this review: This review examines results from neurobiologic research in an attempt to both elucidate the pathophysiology of autism and guide the development of pharmacologic agents for the treatment of associated symptoms. The safety and efficacy data of drugs currently in clinical use for the treatment of these symptoms, as well as pharmaceuticals currently under development, are discussed. What the reader will gain: This comprehensive review will deepen the reader's current understanding of the research guiding the pharmacologic treatment of symptoms associated with autism and related PDDs. Areas of focus for future research are also discussed. The need for large-scale investigation of some commonly used pharmacologic agents, in addition to the development of drugs with improved efficacy and safety profiles, is made evident. Take home message: Despite progress in the development of pharmacologic treatments for a number of interfering symptom domains associated with autism and other PDDs, a great deal of work remains.",
keywords = "Aripiprazole, Autism, Autistic disorder, Methylphenidate, PDDs, Risperidone, Treatment",
author = "Wink, {Logan K.} and Plawecki, {Martin H.} and Erickson, {Craig A.} and Stigler, {Kimberly A.} and McDougle, {Christopher J.}",
year = "2010",
month = "9",
doi = "10.1517/14728214.2010.487860",
language = "English",
volume = "15",
pages = "481--494",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs for the treatment of symptoms associated with autism spectrum disorders

AU - Wink, Logan K.

AU - Plawecki, Martin H.

AU - Erickson, Craig A.

AU - Stigler, Kimberly A.

AU - McDougle, Christopher J.

PY - 2010/9

Y1 - 2010/9

N2 - Importance of the field: Autism spectrum disorders, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders defined by qualitative impairment in social interaction, impaired communication and stereotyped patterns of behavior. The most common forms of PDD are autistic disorder (autism), Asperger's disorder and PDD not otherwise specified. Recent surveillance studies reveal an increase in the prevalence of autism and related PDDs. The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families. Areas covered in this review: This review examines results from neurobiologic research in an attempt to both elucidate the pathophysiology of autism and guide the development of pharmacologic agents for the treatment of associated symptoms. The safety and efficacy data of drugs currently in clinical use for the treatment of these symptoms, as well as pharmaceuticals currently under development, are discussed. What the reader will gain: This comprehensive review will deepen the reader's current understanding of the research guiding the pharmacologic treatment of symptoms associated with autism and related PDDs. Areas of focus for future research are also discussed. The need for large-scale investigation of some commonly used pharmacologic agents, in addition to the development of drugs with improved efficacy and safety profiles, is made evident. Take home message: Despite progress in the development of pharmacologic treatments for a number of interfering symptom domains associated with autism and other PDDs, a great deal of work remains.

AB - Importance of the field: Autism spectrum disorders, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders defined by qualitative impairment in social interaction, impaired communication and stereotyped patterns of behavior. The most common forms of PDD are autistic disorder (autism), Asperger's disorder and PDD not otherwise specified. Recent surveillance studies reveal an increase in the prevalence of autism and related PDDs. The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families. Areas covered in this review: This review examines results from neurobiologic research in an attempt to both elucidate the pathophysiology of autism and guide the development of pharmacologic agents for the treatment of associated symptoms. The safety and efficacy data of drugs currently in clinical use for the treatment of these symptoms, as well as pharmaceuticals currently under development, are discussed. What the reader will gain: This comprehensive review will deepen the reader's current understanding of the research guiding the pharmacologic treatment of symptoms associated with autism and related PDDs. Areas of focus for future research are also discussed. The need for large-scale investigation of some commonly used pharmacologic agents, in addition to the development of drugs with improved efficacy and safety profiles, is made evident. Take home message: Despite progress in the development of pharmacologic treatments for a number of interfering symptom domains associated with autism and other PDDs, a great deal of work remains.

KW - Aripiprazole

KW - Autism

KW - Autistic disorder

KW - Methylphenidate

KW - PDDs

KW - Risperidone

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77955871463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955871463&partnerID=8YFLogxK

U2 - 10.1517/14728214.2010.487860

DO - 10.1517/14728214.2010.487860

M3 - Article

VL - 15

SP - 481

EP - 494

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -